Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01549613
Other study ID # 11-11-03-06
Secondary ID
Status Completed
Phase Phase 4
First received February 8, 2012
Last updated July 7, 2014
Start date May 2012
Est. completion date July 2013

Study information

Verified date July 2014
Source University of Cincinnati
Contact n/a
Is FDA regulated No
Health authority United States: Institutional Review Board
Study type Interventional

Clinical Trial Summary

This is a prospective, randomized clinical trial comparing daptomycin to vancomycin in the Emergency Department (ED) treatment of complicated skin and skin structure infection in the Rapid Diagnosis and Treatment Center (RDTC). In brief, a convenience sample of patients who are admitted to the RDTC cellulitis protocol in the ED will be randomized to either vancomycin, which is currently an accepted care standard in the RDTC cellulitis protocol, or daptomycin, which is the experimental treatment in this study. The primary hypothesis is that daptomycin treatment is as efficacious as standard therapy in the treatment of ED cellulitis.


Description:

Specific Aim 1: Compare the efficacy of daptomycin to the efficacy of vancomycin for the treatment of complicated skin and skin structure infection in the ED. Patients eligible for the RDTC Cellulitis Treatment Protocol will be screened for inclusion in the study. After informed consent, patients will be randomized to receive either daptomycin or vancomycin (1:1 ratio). A case report form (CRF) detailing medical history, clinical characteristics, and treatments will be completed. The patients will be evaluated for meeting RDTC discharge criteria. The following time points will be collected: 1. actual time patient meets discharge criteria based on the RDTC cellulitis protocol; 2. time of disposition defined as the time treating physician writes discharge orders; and, 3. time the patient actually leaves the emergency department. Subsequently, the patient will be followed up by telephone to ascertain whether a change in antibiotic therapy or a return ED visit for complicated skin and skin structure infection occurred within 30 days of the initial RDTC enrollment Specific Aim 2: Compare the change in area and erythema of the cellulitic lesion between patients treated with daptomycin and patients treated with vancomycin. Patients enrolled in the study will have serial digital photographs of their primary lesion taken. The images will be processed blinded to clinical data and asynchronous to the ED stay. The change in lesion area and erythema will be calculated.


Recruitment information / eligibility

Status Completed
Enrollment 104
Est. completion date July 2013
Est. primary completion date July 2013
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Admitted to RDTC to the Cellulitis Protocol

- 18 yrs old or greater

- Able and willing to give informed consent

- Hemodynamically stable (systolic blood pressure >90mmHg and heart rate <120 beats per minute)

Exclusion Criteria:

- Antibiotics given prior to enrollment

- Suspected necrotizing infection

- Diabetic foot ulcer

- Genitourinary involvement

- Post operative infection (not including simple wound closure infection)

- Suspected gouty or septic arthritis

- Chronic Lymphangitis

- Requiring routine hemodialysis

- Patient reported allergy to Vancomycin

- Patient reported allergy to Daptomycin

- Participation in another investigational treatment study within 30 days prior to enrollment

- Prisoner

- Pregnant or breast-feeding

- Complicated skin and skin structure infection of the face

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment


Intervention

Drug:
Daptomycin
• Daptomycin will be given in a one-time dose of 4mg/kg in a one-time dose to be infused over 2 minutes at the initiation of patient therapy in the RDTC cellulitis protocol.
Vancomycin
• Vancomycin will be given in a dose of 15mg/kg at baseline and again at 12 hours to be infused over 1 to 2 hours.

Locations

Country Name City State
United States University of Cincinnati, Dept. of Emergency Medicine Cincinnati Ohio

Sponsors (1)

Lead Sponsor Collaborator
University of Cincinnati

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Satisfaction of Discharge Criteria RDTC cellulitis protocol discharge criteria Time point at which outcome measure is assessed 30 days from the date of admission. No
Secondary Digital and Infrared Imaging Change in lesion area and temperature Time frame begins on admission to RDTC for cellulitis and measurements will be taken every 2hour times 2 and every 4 hours until discharge from the RDTC. No
See also
  Status Clinical Trial Phase
Completed NCT02864420 - Hospitalization at Home: The Acute Care Home Hospital Program for Adults N/A
Completed NCT00746109 - Study of Wound Packing After Superficial Skin Abscess Drainage Phase 4
Completed NCT03296280 - Evaluation of Implementation of a National Point-of-Care Ultrasound Training Program
Not yet recruiting NCT01947660 - Continuous Regional Anesthesia for Septic Limb Orthopedic Surgery N/A
Completed NCT01876628 - Adjunctive Clindamycin for Cellulitis: C4C Trial. Phase 4
Active, not recruiting NCT01706913 - Study Assessing Impact of Dermatology Consultation for Patients Admitted With Cellulitis N/A
Completed NCT03474523 - Effectiveness of Diathermy-Radiofrecuency Compared With Cavitation in Cellulitis Treatment N/A
Recruiting NCT03312946 - Effect of Vibro-oscillatory Therapy for Improvement of Body Contour and Appearance of Cellulite. N/A
Active, not recruiting NCT05226260 - Decreasing Antibiotic Duration for Skin and Soft Tissue Infection Using Behavioral Economics in Primary Care N/A
Active, not recruiting NCT03785834 - The Effect of Histopathologic Analysis and Tissue Cultures on Inpatient Management of Cellulitis and Pseudocellulitis
Completed NCT01029782 - Comparison of Intravenous Cefazolin Plus Oral Probenecid With Oral Cephalexin for the Treatment of Cellulitis Phase 2
Completed NCT00676130 - Study of New Antibiotic Regimen for the Treatment of Uncomplicated Cellulitis in Emergency Department Patients N/A
Not yet recruiting NCT03917134 - Prevention of Vaginal Cellulitis or Vaginal Cuff Abscess After Laparoscopic Hysterectomy N/A
Completed NCT02230813 - Predictors of Oral Antibiotic Treatment Failure in Emergency Department Patients With Cellulitis N/A
Completed NCT01557426 - Soft Tissue Ultrasound of Infections Phase 1
Completed NCT01339091 - Efficacy and Safety of Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections Phase 3
Completed NCT00984022 - Aquacel Versus Iodoform Gauze for Filling Abscess Cavity Following Incision and Drainage Phase 2
Completed NCT04091672 - RECELL® System Combined With Meshed Autograft for Reduction of Donor Skin Harvesting in Soft Tissue Reconstruction N/A
Completed NCT05023200 - The Personalised Antibiotic Duration for Cellulitis (PAD-C) Study
Terminated NCT02087527 - Use of Corticosteroids in Children With Cellulitis N/A